AKT1 and hepatocellular carcinoma: The precision associated with this therapy allows the development of exosome‐based therapies for HCC to target important oncogenic pathways particularly alterations in the PI3K/Akt/mTOR pathway, that could lead to more effective clinical outcomes [38].